CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
T3 with DCD tapered Prevail implant +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02161874
NCT02161874N/ACompleted
CompareCT.gov

A Prospective, Randomized-controlled Evaluation of Biomet 3i's T3 Implant System for Integration Success and the Preservation of Crestal Bone

ZimVie·interventional·Posted Jun 12, 2014·Updated May 22, 2026

In Brief

A clinical study evaluating T3 with DCD tapered Prevail implant and Nanotite Certain tapered implant for Partial Edentulism and Tooth Disease. Completed, enrolled 40 participants across 4 sites in 4 countries.

Detailed Summary

This study evaluates the T3 implant system for the preservation of alveolar crestal bone and the establishment of initial integration. The new surface-treated features of the implant may contribute to improved soft and hard tissue healing. The success rate of the T3 implant will be no different than that of the control implant, which possess similar geometry but different surface treatments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPartial Edentulism, Tooth Disease
CountriesBelgium, France, Germany, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 12, 2014
Enrollment StartApr 1, 2013
Primary CompletionJan 1, 2019
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 12.1 years ago

Interventions

T3 with DCD tapered Prevail implantdevice

T3 with DCD implant with Certain (internal) connection and platform-switch design

Nanotite Certain tapered implantdevice

Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design